XENE — Xenon Pharmaceuticals Inc.

Summary of Xenon Pharmaceuticals Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Cash Position: As of September 30, 2025, Xenon reported cash, cash equivalents, and marketable securities totaling $555.3 million, down from $754.4 million at the end of 2024.
• Funding Outlook: The company anticipates sufficient cash to fund operations into 2027, supporting multiple late-stage clinical programs.

2. Strategic Updates and Business Highlights:

• Phase III X-TOLE2 Study: Completed randomization of 380 patients for the azetukalner study targeting focal onset seizures, exceeding the initial goal of 360. Top line data is expected in early 2026.
• Expansion into Neuropsychiatry: Initiated Phase III trials (X-NOVA2 and X-NOVA3) for azetukalner in major depressive disorder (MDD) and X-CEED for bipolar depression (BPD).
• Pipeline Development: Progress in early-stage programs, with both Nav1.7 and Kv7 modulators (XEN1701 and XEN1120) moving into Phase I studies.
• Leadership Update: Introduction of Tucker Kelly as the new CFO, bringing experience from Deciphera Pharmaceuticals.

3. Forward Guidance and Outlook:

• NDA Filing: The company is preparing for an NDA submission for azetukalner, contingent on positive results from the X-TOLE2 study.
• Clinical Milestones: Anticipated data from the X-TOLE2 study will guide further development and potential commercialization strategies.
• Commercial Strategy: Plans to ramp up operations in preparation for a potential launch in 2027, with increased operational expenses expected in 2026.

4. Bad News, Challenges, or Points of Concern:

• Cash Decrease: The significant decline in cash reserves raises concerns about funding future operations and clinical trials.
• Competitive Landscape: Increased competition in the epilepsy market, with recent Phase II readouts from competitors potentially impacting azetukalner's market positioning.
• Interim Analysis Absence: The absence of an interim analysis for the MDD trials raises questions about the study's adaptability and responsiveness to early data insights.

5. Notable Q&A Insights:

• Top Line Data Expectations: The company plans to provide a balanced view of efficacy and safety in the top line data release for X-TOLE2, similar to previous disclosures.
• Screening and Enrollment: The increase in randomized patients was attributed to heightened interest in azetukalner, with no significant impact on powering assumptions.
• Cenobamate Usage: Anticipated higher usage of cenobamate in the Phase III study compared to Phase II, with ongoing assessments of its impact on efficacy and tolerability.
• Bipolar Depression Study Design: The decision to use MADRS over HAM-D for BPD was based on historical precedents and the need for a robust primary endpoint.

This summary encapsulates the key points from Xenon Pharmaceuticals' Q3 2025 earnings call, highlighting financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A session.